-

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June:

  • William Blair 41st Annual Growth Stock Conference (Virtual) on Thursday, June 3, 2021 at 1:00 pm (EDT)
  • BioPharma Sustainability Roundtable’s CEO Investor Forum on Monday, June 7, 2021 at 1:35 pm (EDT)
  • Goldman Sachs 42nd Annual Global Healthcare Conference (Virtual) on Tuesday, June 8, 2021 at 8:00 am (EDT)
  • Guggenheim’s “Biopharma’s Next Decade: Views from the Top on Global Strategy and Innovation” Series on Monday, June 28, 2021 at 11:00 am (EDT)

The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Contacts

Incyte
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com

Investors
Christine Chiou
+1 302 274 4773
cchiou@incyte.com

Incyte

NASDAQ:INCY

Release Summary
Incyte to Present at Upcoming Investor Conferences
Release Versions

Contacts

Incyte
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com

Investors
Christine Chiou
+1 302 274 4773
cchiou@incyte.com

More News From Incyte

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Present at Upcoming Investor Conferences...

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...

Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

WILMINGTON, Del.--(BUSINESS WIRE)--Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the EU for Adults with Moderate Atopic Dermatitis...
Back to Newsroom